Use access key #2 to skip to page content.
$0.28 0.00 (0.00%)
8/20/2008 3:59 PM

Sonus Pharmaceuticals, Inc. (SNUS)

CAPS Rating:
No stars

The Company focuses on the development of oncology drugs which provide better therapeutic alternatives for cancer patients, including improved efficacy, safety, tolerability and are more convenient to use.

Rating a stock in CAPS consists of three components:

Your call - Will this stock outperform or underperform the S&P 500? Successful picks are measured in terms of whether or not you were correct and by how many percentage points.

Your time frame - A guideline for other members to see whether your thinking is short or long-term. Time frame is also used to calculate the stock rating, but is not used in the scoring of your pick.

Your pitch - Here's your chance to offer more detailed thoughts, analysis, concerns, or the rationale behind your call. The pitch is optional and may be added later.

Each time you rate a stock, CAPS updates the community intelligence for the company, which may or may not change its CAPS rating. For more information, visit the Help tab at the top of the page.

Ticker Not Ratable

SNUS doesn't currently meet the $100M market cap / $1.50 stock price minimum. (Learn More)

What the Community Thinks

Total Members

65 Outperforms
4 Underperforms
 

All-Stars

8 Outperforms
0 Underperforms
 

Wall Street

1 Outperforms
0 Underperforms
 

Members bullish on SNUS are also bullish on:

Members bearish on SNUS are also bearish on:

Ticker Tags

Micro Cap (4824), Diagnostic Substances (53)
Suggest a tag

Sonus Pharmaceuticals, Inc. At A Glance

Current Price: $0.28
Last Trade Time: 8/20/2008 3:59 PM
Open: $0.00
Previous Close: $0.28
Daily Range: $0.25 - $0.28
52-Week Range: $4.13 - $81.36
Volume: 209,367
Market Cap: $10.39M
P/E Ratio: 0.00
Compare Our Special Broker Offers!

Stock Trends

SNUS VS S&P 500 (SPY)

SNUS 12 month chart vs. S&P

News & Discussion Boards

Other News Headlines for SNUS

More Headlines...

Top Bull Pitch

Recs

4

Sonus Pharmaceuticals, Inc. (SNUS)

Avatar stockpick077 (< 20) Submitted: 8/29/07 1:54 PM

Their Lead product Tocosol is in P-III trials with results due by end-September 2007. The trial design ensures that Tocosol will be considered successful as long as it can be at least 75% as effective as the Taxol being administered in the control arm. The details of the side-effect profile from the...More

Replies: 0 | Reply | Permalink

Top Bear Pitch

There are no pitches that meet the Top Bear criteria. Explain

If this upsets you, start recommending pitches below!

CAPS Members

picks per page. CHANGE

Results 1 - 5 of 13 :   1 2 3 Next »

Recs

4

 (SNUS)

Avatar stockpick077 (< 20) Submitted: 8/29/07 1:54 PM : Outperform Start Price: $3.96 SNUS Score: -55.09

Their Lead product Tocosol is in P-III trials with results due by end-September 2007. The trial design ensures that Tocosol will be considered successful as long as it can be at least 75% as effective as the Taxol being administered in the control arm. The details of the side-effect profile from the P-III trial has leaked and it appears that Tocosol is doing really well on that front. Odds are that the trial will meet its end-point with comparable efficacy and superior safety profile.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SNUS)

Avatar preachertim (24.44) Submitted: 6/13/07 12:15 PM : Outperform Start Price: $5.71 SNUS Score: -54.82

recieved a patent on a new cancer drug 6/13/07 - already price has moved up $0.04.

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SNUS)

Avatar rphopper (75.67) Submitted: 5/17/07 4:57 PM : Outperform Start Price: $5.50 SNUS Score: -54.08

new drug to enter the market in 2008

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SNUS)

Avatar frherma (< 20) Submitted: 5/08/07 7:39 PM : Outperform Start Price: $5.40 SNUS Score: -54.53

superior cancer durg

Report this Post Replies: 0 | Reply | Permalink

Recs

0

 (SNUS)

Avatar SlyGuyRy (< 20) Submitted: 2/01/07 9:23 AM : Outperform Start Price: $5.60 SNUS Score: -57.40

Phase III tests of their flagship drug are underway and this reformula should be able to be FDA approved either the 4th Quarter of 2007 or FY2008. Double by 2008.

Report this Post Replies: 0 | Reply | Permalink

Results 1 - 5 of 13 :   1 2 3 Next »

Wall Street

Results 1 - 1 of 1  

picks per page. CHANGE Expand All Pitches

Top
Pick
Member NameMember RatingStart
Date
CallTime FrameStart
Price
Stock
Gain
S&P
Gain
ScorePitch
TrackEveillard 94.20 09/30/07 Outperform NS $0.62-54.85%-41.05%-13.81 Toggle the visibility of 60-Second Pitch and replies

Results 1 - 1 of 1  

Beat this Stock

Clicking "Beat this Stock!" will bring you to a company with a higher rating than the one you're currently viewing.

Even though CAPS shows only one- to five-star rankings, behind the scenes, all companies in CAPS have a distinct numerical ranking. In other words, there is a No. 1 stock in CAPS and a worst-ranked stock in CAPS. When you arrive at the top-ranked stock, clicking "Beat this Stock!" will cause the page to refresh.

That is, until there is a new No. 1 stock!

These companies do not represent formal Motley Fool recommendations. Please do your own due diligence before investing. Fool on.

Featured Broker Partners